SBE13
SBE13 is a potent and selective Plk1 inhibitor, with an IC50 of 200 pM; SBE13 poorly inhibits Plk2 (IC50>66 μM) or Plk3 (IC50=875 nM).
For research use only. We do not sell to patients.
- CAS No.: 775294-82-1
- Formula: C24H27ClN2O4
- Molecular Weight:442.94
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
PLK1 200 pM (IC50) |
PLK3 875 nM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-431 | EC50 |
33 μM
Compound: 38; SBE13
|
Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation incubated for 72 hrs
Antiproliferative activity against human A-431 cells assessed as reduction in cell proliferation incubated for 72 hrs
|
[PMID: 35878418] |
| A549 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| Detroit 562 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human Detroit 562 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human Detroit 562 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HCT-15 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HCT-15 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HeLa | EC50 |
18 μM
Compound: 13, SBE13
|
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 72 hrs
Antiproliferative activity against human HeLa cells assessed as growth inhibition after 24 to 72 hrs
|
[PMID: 25304894] |
| HeLa | EC50 |
18 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| HT-29 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| LN-229 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human LN-229 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| MCF7 | EC50 |
12 μM
Compound: 38; SBE13
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell proliferation incubated for 72 hrs
Antiproliferative activity against human MCF7 cells assessed as reduction in cell proliferation incubated for 72 hrs
|
[PMID: 35878418] |
| PC-3 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| SK-OV-3 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| SKW 6.4 | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human SKW 6.4 cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human SKW 6.4 cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
| U2OS | EC50 |
5 μM
Compound: 38; SBE13
|
Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs
Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 72 hrs
|
[PMID: 35878418] |
In Vitro
SBE13 significantly reduce cell proliferation and induce apoptosis in HeLa cells, with an EC50 of 18 μM[1]. SBE13 (1-100 μM) shows no effect on Caspase 3/7 activity in NIH-3T3 cells. SBE13 (66 and 100 μM) does not change morphology after treatment of primary cells. SBE13 (10 and 100 μM) reduces pRb staining in primary cells, and this indicates a G0/G1 arrest[2]. SBE13 (66 and 100 μM) increases levels of cyclin B1, phospho histone H3, Wee1, Emi1 and securin, and results in cleavage of Cdc27 in HeLa cells. SBE13 (10 and 100 μM) also induces apoptosis of HeLa cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 775294-82-1
-
Molecular Weight 442.94
-
Formula C24H27ClN2O4
-
SMILES
COC1=CC=C(CCNCC2=CC=C(OCC3=CC=C(Cl)N=C3)C(OC)=C2)C=C1OC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
[1]. Keppner S, et al. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1. ChemMedChem. 2009 Nov;4(11):1806-9. [Content Brief]
[2]. Keppner S, et al. Fate of primary cells at the G?/S boundary after polo-like kinase 1 inhibition by SBE13. Cell Cycle. 2011 Feb 15;10(4):708-20. Epub 2011 Feb 15. [Content Brief]
[3]. Keppner S, et al. Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle. 2010 Feb 15;9(4):761-73. Epub 2010 Feb 16. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)